Portfolio Holdings Detail for ISIN IE00BDZVHG35
Deprecated: strlen(): Passing null to parameter #1 ($string) of type string is deprecated in /var/www/liquidata/show_ticker_holding_ETFs.php on line 77
Stock Name / Fund iShares Nasdaq US Biotechnology UCITS ETF USD (Dist)
Issuer Blackrock

ETF Ticker BTEE(USD) LSE
ETF Ticker BTEE.L(GBP) LSE

Holdings detail for CRNX

Stock Name	Crinetics Pharmaceuticals Inc
Ticker	CRNX(USD) NASDAQ
TYPE	Common Stock
Country	USA
ISIN	US22663K1079
LEI	549300Q1CNFXK5P31D28

Show aggregate CRNX holdings

News associated with CRNX

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Receives $68.86 Consensus Price Target from Brokerages: Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Get Free Report) has been given a consensus rating of “Moderate Buy” by the nine research firms that are covering the stock, Marketbeat.com reports. Two research analysts have rated the stock with a hold recommendation and seven have issued a buy recommendation on the company. The average twelve-month price objective […] - 2025-08-19 02:16:54
Crinetics Pharmaceuticals (NASDAQ:CRNX) Price Target Cut to $86.00 by Analysts at JMP Securities: Crinetics Pharmaceuticals (NASDAQ:CRNX – Free Report) had its target price reduced by JMP Securities from $90.00 to $86.00 in a report published on Monday,Benzinga reports. JMP Securities currently has a market outperform rating on the stock. Several other research firms have also recently weighed in on CRNX. HC Wainwright reaffirmed a “buy” rating and set […] - 2025-08-12 04:47:05
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Shares Sold by Victory Capital Management Inc.: Victory Capital Management Inc. lowered its position in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Free Report) by 10.7% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 251,331 shares of the company’s stock after selling 30,120 shares during the quarter. Victory Capital Management Inc.’s holdings in […] - 2025-07-25 06:06:53
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Receives Average Recommendation of “Moderate Buy” from Brokerages: Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Get Free Report) has been given an average recommendation of “Moderate Buy” by the ten brokerages that are currently covering the firm, MarketBeat.com reports. Two investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. The average 12-month target price […] - 2025-07-22 07:55:07
New York State Common Retirement Fund Sells 17,508 Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX): New York State Common Retirement Fund lessened its holdings in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Free Report) by 11.3% during the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 137,918 shares of the company’s stock after selling 17,508 shares during the quarter. New York State Common […] - 2025-07-22 07:13:05
Teacher Retirement System of Texas Decreases Holdings in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX): Teacher Retirement System of Texas decreased its position in shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Free Report) by 6.5% in the 1st quarter, Holdings Channel reports. The fund owned 22,442 shares of the company’s stock after selling 1,561 shares during the quarter. Teacher Retirement System of Texas’ holdings in Crinetics Pharmaceuticals were worth $753,000 […] - 2025-07-15 04:24:35
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Receives Consensus Rating of “Moderate Buy” from Brokerages: Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Get Free Report) have been assigned an average recommendation of “Moderate Buy” from the ten analysts that are presently covering the company, Marketbeat.com reports. One analyst has rated the stock with a hold rating and nine have given a buy rating to the company. The average 1 year […] - 2025-07-02 04:30:55
Insider Selling: Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Insider Sells $3,141,877.09 in Stock: Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Get Free Report) insider Stephen F. Betz sold 97,483 shares of the stock in a transaction dated Thursday, June 12th. The stock was sold at an average price of $32.23, for a total transaction of $3,141,877.09. Following the transaction, the insider now owns 99,713 shares of the company’s stock, valued […] - 2025-06-19 05:10:52
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Shares Acquired by Mackenzie Financial Corp: Mackenzie Financial Corp grew its holdings in shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Free Report) by 8.8% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 5,422 shares of the company’s stock after purchasing an additional 440 shares during the period. Mackenzie Financial Corp’s holdings […] - 2025-06-05 06:18:55
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Receives Average Rating of “Moderate Buy” from Brokerages: Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Get Free Report) have received an average rating of “Moderate Buy” from the eleven ratings firms that are presently covering the stock, MarketBeat reports. One investment analyst has rated the stock with a hold rating and ten have given a buy rating to the company. The average 1 […] - 2025-06-02 02:10:52
State of Wyoming Makes New Investment in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX): State of Wyoming purchased a new stake in shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 985 shares of the company’s stock, valued at approximately $50,000. Several other large investors […] - 2025-05-30 05:06:48
Bank of America Corp DE Cuts Stock Holdings in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX): Bank of America Corp DE decreased its position in shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Free Report) by 15.4% during the fourth quarter, HoldingsChannel reports. The institutional investor owned 235,281 shares of the company’s stock after selling 42,792 shares during the period. Bank of America Corp DE’s holdings in Crinetics Pharmaceuticals were worth $12,030,000 […] - 2025-05-23 06:26:56
BNP Paribas Financial Markets Sells 5,683 Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX): BNP Paribas Financial Markets decreased its stake in shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Free Report) by 27.1% in the fourth quarter, Holdings Channel.com reports. The fund owned 15,259 shares of the company’s stock after selling 5,683 shares during the period. BNP Paribas Financial Markets’ holdings in Crinetics Pharmaceuticals were worth $780,000 at the […] - 2025-05-23 04:58:51
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Purchases 6,719 Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX): MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Free Report) by 14.5% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 53,163 shares of the company’s stock after acquiring an additional 6,719 shares during […] - 2025-05-21 05:40:53
Ameriprise Financial Inc. Has $18.16 Million Position in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX): Ameriprise Financial Inc. lifted its stake in shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Free Report) by 110.8% during the fourth quarter, Holdings Channel reports. The fund owned 355,174 shares of the company’s stock after buying an additional 186,681 shares during the quarter. Ameriprise Financial Inc.’s holdings in Crinetics Pharmaceuticals were worth $18,159,000 as of […] - 2025-05-16 05:03:19
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Given Consensus Recommendation of “Moderate Buy” by Analysts: Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Get Free Report) has earned an average recommendation of “Moderate Buy” from the thirteen brokerages that are presently covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a hold recommendation and twelve have assigned a buy recommendation to the company. The average 1 year target […] - 2025-05-08 02:22:53
Envestnet Asset Management Inc. Buys 8,751 Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX): Envestnet Asset Management Inc. boosted its position in shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Free Report) by 16.1% during the 4th quarter, HoldingsChannel reports. The fund owned 63,077 shares of the company’s stock after buying an additional 8,751 shares during the quarter. Envestnet Asset Management Inc.’s holdings in Crinetics Pharmaceuticals were worth $3,225,000 as […] - 2025-04-25 04:24:46
Legal & General Group Plc Buys 12,538 Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX): Legal & General Group Plc lifted its position in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Free Report) by 16.4% in the 4th quarter, HoldingsChannel.com reports. The fund owned 88,939 shares of the company’s stock after acquiring an additional 12,538 shares during the quarter. Legal & General Group Plc’s holdings in Crinetics Pharmaceuticals were worth $4,547,000 as […] - 2025-04-22 04:47:14
Crinetics Pharmaceuticals (NASDAQ:CRNX) Shares Unloaded Rep. Josh Gottheimer: Representative Josh Gottheimer (D-New Jersey) recently sold shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX). In a filing disclosed on April 10th, the Representative disclosed that they had sold between $1,001 and $15,000 in Crinetics Pharmaceuticals stock on March 19th. The trade occurred in the Representative’s “MORGAN STANLEY – SELECT UMA ACCOUNT # 1” account. Representative Josh […] - 2025-04-14 03:02:59
Corebridge Financial Inc. Buys 1,992 Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX): Corebridge Financial Inc. boosted its stake in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Free Report) by 4.8% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 43,599 shares of the company’s stock after buying an additional 1,992 shares during the period. Corebridge Financial Inc.’s holdings […] - 2025-04-02 06:46:52
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Shares Bought by Vanguard Group Inc.: Vanguard Group Inc. grew its holdings in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Free Report) by 44.6% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 9,089,391 shares of the company’s stock after acquiring an additional 2,801,736 shares during the quarter. Vanguard Group […] - 2025-04-02 05:24:53
16,000 Shares in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Purchased by KLP Kapitalforvaltning AS: KLP Kapitalforvaltning AS bought a new position in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 16,000 shares of the company’s stock, valued at approximately $818,000. A number of other hedge funds have also added to […] - 2025-04-01 05:14:54
Crinetics Pharmaceuticals (NASDAQ:CRNX) Coverage Initiated at Stifel Nicolaus: Analysts at Stifel Nicolaus began coverage on shares of Crinetics Pharmaceuticals (NASDAQ:CRNX – Get Free Report) in a report released on Tuesday, MarketBeat Ratings reports. The firm set a “buy” rating and a $60.00 price target on the stock. Stifel Nicolaus’ price target would suggest a potential upside of 73.86% from the stock’s previous close. […] - 2025-03-27 04:00:59
Arizona State Retirement System Grows Holdings in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX): Arizona State Retirement System boosted its holdings in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Free Report) by 21.6% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 23,469 shares of the company’s stock after purchasing an additional 4,168 shares during the […] - 2025-03-14 06:10:48
Assetmark Inc. Purchases 1,014 Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX): Assetmark Inc. raised its position in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Free Report) by 5.9% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 18,161 shares of the company’s stock after acquiring an additional 1,014 shares during the quarter. Assetmark Inc.’s holdings in Crinetics Pharmaceuticals […] - 2025-03-12 06:11:03
Keybank National Association OH Has $478,000 Position in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX): Keybank National Association OH boosted its stake in shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Free Report) by 14.4% in the 4th quarter, HoldingsChannel.com reports. The fund owned 9,352 shares of the company’s stock after purchasing an additional 1,176 shares during the quarter. Keybank National Association OH’s holdings in Crinetics Pharmaceuticals were worth $478,000 at […] - 2025-03-10 05:54:54
Handelsbanken Fonder AB Buys 2,800 Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX): Handelsbanken Fonder AB raised its stake in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Free Report) by 14.7% during the fourth quarter, Holdings Channel.com reports. The institutional investor owned 21,800 shares of the company’s stock after purchasing an additional 2,800 shares during the quarter. Handelsbanken Fonder AB’s holdings in Crinetics Pharmaceuticals were worth $1,115,000 at the end […] - 2025-02-28 07:25:04
New York State Common Retirement Fund Purchases 7,735 Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX): New York State Common Retirement Fund lifted its position in shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Free Report) by 5.2% during the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 155,426 shares of the company’s stock after purchasing an additional 7,735 shares during the quarter. New York State Common Retirement Fund’s holdings in Crinetics […] - 2025-02-27 06:51:01
Add Up The Pieces: VBK Could Be Worth $335: Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. - 2025-02-13 13:24:24
TD Cowen Begins Coverage on Crinetics Pharmaceuticals (NASDAQ:CRNX): Analysts at TD Cowen started coverage on shares of Crinetics Pharmaceuticals (NASDAQ:CRNX – Get Free Report) in a research note issued on Tuesday, MarketBeat.com reports. The firm set a “buy” rating on the stock. CRNX has been the subject of a number of other reports. Wolfe Research started coverage on shares of Crinetics Pharmaceuticals in […] - 2025-02-13 08:26:44

iShares Nasdaq US Biotechnology UCITS ETF USD (Dist) CRNX holdings

Date	Number of CRNX Shares Held	Base Market Value of CRNX Shares	Local Market Value of CRNX Shares	Change in CRNX Shares Held	Change in CRNX Base Value	Current Price per CRNX Share Held	Previous Price per CRNX Share Held
2025-11-11 (Tuesday)	61,187	USD 2,627,370	USD 2,627,370	0	USD 91,169	USD 42.94	USD 41.45
2025-11-10 (Monday)	61,187	USD 2,536,201	USD 2,536,201	156	USD 94,961	USD 41.45	USD 40
2025-11-07 (Friday)	61,031	USD 2,441,240	USD 2,441,240	0	USD -212,998	USD 40	USD 43.49
2025-11-06 (Thursday)	61,031	USD 2,654,238	USD 2,654,238	156	USD 65,224	USD 43.49	USD 42.53
2025-11-05 (Wednesday)	60,875	USD 2,589,014	USD 2,589,014	0	USD 1,218	USD 42.53	USD 42.51
2025-11-04 (Tuesday)	60,875	USD 2,587,796	USD 2,587,796	157	USD -13,970	USD 42.51	USD 42.85
2025-11-03 (Monday)	60,718	USD 2,601,766	USD 2,601,766	0	USD -39,467	USD 42.85	USD 43.5
2025-10-31 (Friday)	60,718	USD 2,641,233	USD 2,641,233	0	USD 13,358	USD 43.5	USD 43.28
2025-10-30 (Thursday)	60,718	USD 2,627,875	USD 2,627,875	785	USD 56,749	USD 43.28	USD 42.9
2025-10-29 (Wednesday)	59,933	USD 2,571,126	USD 2,571,126	314	USD 63,551	USD 42.9	USD 42.06
2025-10-28 (Tuesday)	59,619	USD 2,507,575	USD 2,507,575	0	USD -135,931	USD 42.06	USD 44.34
2025-10-27 (Monday)	59,619	USD 2,643,506	USD 2,643,506	0	USD 199,723	USD 44.34	USD 40.99

Share price and value of shares held is calculated on the adjusted close price of each day (row). Changes between days reflect the gain/loss of the portfolio as a result of changes in the adjusted close price and changes in the holdings

Share Trades of CRNX by Blackrock for IE00BDZVHG35

Show aggregate share trades of CRNX

Date Action Quantity Market High Market Low Likely Trade Price Likely Trade Value (Profit/Loss) Average Price previous trades
2025-11-10 BUY 156 41.560 39.890 40.057 USD 6,249 38.70
2025-11-06 BUY 156 43.890 42.380 42.531 USD 6,635 38.66
2025-11-04 BUY 157 42.780 41.510 41.637 USD 6,537 38.62
2025-10-30 BUY 785 44.695 42.350 42.585 USD 33,429 38.55
2025-10-29 BUY 314 42.900 43.855 43.759 USD 13,740 38.52
2025-10-22 SELL -628 40.430 42.720 42.491 USD -26,684 38.43 Loss of -2,549 on sale
2025-10-20 BUY 314 42.450 42.810 42.774 USD 13,431 38.38
2025-10-17 BUY 784 41.570 42.795 42.672 USD 33,455 38.36
2025-10-15 BUY 1,248 44.150 45.960 45.779 USD 57,132 38.33
2025-10-03 BUY 1,085 40.860 42.010 41.895 USD 45,456 38.28
2025-10-02 BUY 155 41.510 42.177 42.110 USD 6,527 38.26
2025-09-30 BUY 310 41.650 43.480 43.297 USD 13,422 38.22
2025-09-29 BUY 310 43.510 47.410 47.020 USD 14,576 38.19
2025-09-25 BUY 310 35.890 36.871 36.773 USD 11,400 38.15
2025-09-18 BUY 163 35.480 35.745 35.718 USD 5,822 38.17
2025-09-17 BUY 489 34.200 35.090 35.001 USD 17,115 38.20
2025-07-17 SELL -326 33.020 33.280 33.254 USD -10,841 38.35 Profit of 1,661 on sale
2025-07-16 BUY 840 31.900 32.670 32.593 USD 27,378 38.39
2025-07-11 SELL -1,280 31.930 32.210 32.182 USD -41,193 38.51 Profit of 8,102 on sale
2025-07-02 BUY 8,800 29.440 30.010 29.953 USD 263,586 38.72
2025-06-25 BUY 320 30.410 30.995 30.937 USD 9,900 38.97
2025-06-20 BUY 1,661 30.160 30.860 30.790 USD 51,142 39.15
2025-06-11 BUY 310 32.330 33.350 33.248 USD 10,307 39.57
2025-06-10 BUY 310 33.080 33.770 33.701 USD 10,447 39.61
2025-06-04 SELL -155 32.130 32.650 32.598 USD -5,053 39.84 Profit of 1,122 on sale
2025-04-23 BUY 155 32.370 32.890 32.838 USD 5,090 42.36
2025-04-10 SELL -1,240 26.850 27.170 27.138 USD -33,651 43.64 Profit of 20,458 on sale
2025-04-08 SELL -155 25.560 27.273 27.102 USD -4,201 44.03 Profit of 2,624 on sale
2025-04-07 SELL -155 26.380 27.230 27.145 USD -4,207 44.23 Profit of 2,649 on sale
2025-04-04 SELL -775 26.890 28.535 28.370 USD -21,987 44.44 Profit of 12,452 on sale
2025-04-01 BUY 1,356 30.620 33.420 33.140 USD 44,938 44.76
2025-03-31 SELL -459 33.540 34.545 34.444 USD -15,810 44.90 Profit of 4,798 on sale
2025-03-21 BUY 2,150 34.420 35.290 35.203 USD 75,686 45.68
2025-03-14 SELL -2,336 34.470 35.630 35.514 USD -82,961 46.47 Profit of 25,587 on sale
2025-03-07 SELL -292 33.280 34.145 34.059 USD -9,945 47.39 Profit of 3,892 on sale
2025-03-04 SELL -146 34.060 34.750 34.681 USD -5,063 48.02 Profit of 1,948 on sale
2025-02-25 BUY 292 32.300 34.795 34.545 USD 10,087 49.26
2025-02-19 SELL -145 36.600 36.740 36.726 USD -5,325 50.22 Profit of 1,956 on sale
2025-02-13 BUY 435 35.260 35.850 35.791 USD 15,569 51.41
2025-02-12 BUY 145 35.210 35.220 35.219 USD 5,107 51.74
2025-02-11 BUY 580 34.930 36.660 36.487 USD 21,162 52.09
2024-12-30 BUY 1,667 50.670 51.280 51.219 USD 85,382 57.37
2024-11-18 SELL -2,055 53.700 55.050 54.915 USD -112,850 58.02 Profit of 6,378 on sale
2024-11-08 SELL -137 60.690 60.930 60.906 USD -8,344 57.77 Loss of -429 on sale
2024-10-21 SELL -137 58.700 58.880 58.862 USD -8,064 0.00 Loss of -8,064 on sale
Market high and low price is on the date.

Date	Action	Quantity	Market High	Market Low	Likely Trade Price	Likely Trade Value (Profit/Loss)	Average Price previous trades
2025-11-10	BUY	156	41.560	39.890	40.057	USD 6,249	38.70
2025-11-06	BUY	156	43.890	42.380	42.531	USD 6,635	38.66
2025-11-04	BUY	157	42.780	41.510	41.637	USD 6,537	38.62
2025-10-30	BUY	785	44.695	42.350	42.585	USD 33,429	38.55
2025-10-29	BUY	314	42.900	43.855	43.759	USD 13,740	38.52
2025-10-22	SELL	-628	40.430	42.720	42.491	USD -26,684	38.43 Loss of -2,549 on sale
2025-10-20	BUY	314	42.450	42.810	42.774	USD 13,431	38.38
2025-10-17	BUY	784	41.570	42.795	42.672	USD 33,455	38.36
2025-10-15	BUY	1,248	44.150	45.960	45.779	USD 57,132	38.33
2025-10-03	BUY	1,085	40.860	42.010	41.895	USD 45,456	38.28
2025-10-02	BUY	155	41.510	42.177	42.110	USD 6,527	38.26
2025-09-30	BUY	310	41.650	43.480	43.297	USD 13,422	38.22
2025-09-29	BUY	310	43.510	47.410	47.020	USD 14,576	38.19
2025-09-25	BUY	310	35.890	36.871	36.773	USD 11,400	38.15
2025-09-18	BUY	163	35.480	35.745	35.718	USD 5,822	38.17
2025-09-17	BUY	489	34.200	35.090	35.001	USD 17,115	38.20
2025-07-17	SELL	-326	33.020	33.280	33.254	USD -10,841	38.35 Profit of 1,661 on sale
2025-07-16	BUY	840	31.900	32.670	32.593	USD 27,378	38.39
2025-07-11	SELL	-1,280	31.930	32.210	32.182	USD -41,193	38.51 Profit of 8,102 on sale
2025-07-02	BUY	8,800	29.440	30.010	29.953	USD 263,586	38.72
2025-06-25	BUY	320	30.410	30.995	30.937	USD 9,900	38.97
2025-06-20	BUY	1,661	30.160	30.860	30.790	USD 51,142	39.15
2025-06-11	BUY	310	32.330	33.350	33.248	USD 10,307	39.57
2025-06-10	BUY	310	33.080	33.770	33.701	USD 10,447	39.61
2025-06-04	SELL	-155	32.130	32.650	32.598	USD -5,053	39.84 Profit of 1,122 on sale
2025-04-23	BUY	155	32.370	32.890	32.838	USD 5,090	42.36
2025-04-10	SELL	-1,240	26.850	27.170	27.138	USD -33,651	43.64 Profit of 20,458 on sale
2025-04-08	SELL	-155	25.560	27.273	27.102	USD -4,201	44.03 Profit of 2,624 on sale
2025-04-07	SELL	-155	26.380	27.230	27.145	USD -4,207	44.23 Profit of 2,649 on sale
2025-04-04	SELL	-775	26.890	28.535	28.370	USD -21,987	44.44 Profit of 12,452 on sale
2025-04-01	BUY	1,356	30.620	33.420	33.140	USD 44,938	44.76
2025-03-31	SELL	-459	33.540	34.545	34.444	USD -15,810	44.90 Profit of 4,798 on sale
2025-03-21	BUY	2,150	34.420	35.290	35.203	USD 75,686	45.68
2025-03-14	SELL	-2,336	34.470	35.630	35.514	USD -82,961	46.47 Profit of 25,587 on sale
2025-03-07	SELL	-292	33.280	34.145	34.059	USD -9,945	47.39 Profit of 3,892 on sale
2025-03-04	SELL	-146	34.060	34.750	34.681	USD -5,063	48.02 Profit of 1,948 on sale
2025-02-25	BUY	292	32.300	34.795	34.545	USD 10,087	49.26
2025-02-19	SELL	-145	36.600	36.740	36.726	USD -5,325	50.22 Profit of 1,956 on sale
2025-02-13	BUY	435	35.260	35.850	35.791	USD 15,569	51.41
2025-02-12	BUY	145	35.210	35.220	35.219	USD 5,107	51.74
2025-02-11	BUY	580	34.930	36.660	36.487	USD 21,162	52.09
2024-12-30	BUY	1,667	50.670	51.280	51.219	USD 85,382	57.37
2024-11-18	SELL	-2,055	53.700	55.050	54.915	USD -112,850	58.02 Profit of 6,378 on sale
2024-11-08	SELL	-137	60.690	60.930	60.906	USD -8,344	57.77 Loss of -429 on sale
2024-10-21	SELL	-137	58.700	58.880	58.862	USD -8,064	0.00 Loss of -8,064 on sale

* (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection

The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close

Shorting History of CRNX

Date	Shorted Volume	Short Exempt Volume	Total Shares Traded	% Shorted
2025-09-19	291,811	10	422,190	69.1%
2025-09-18	255,311	4,887	441,317	57.9%
2025-09-17	188,956	0	259,138	72.9%
2025-09-16	203,554	46	341,724	59.6%
2025-09-15	274,635	30	448,716	61.2%
2025-09-12	212,918	4	332,544	64.0%
2025-09-11	387,813	4,439	687,673	56.4%
2025-09-10	271,583	180	472,484	57.5%
2025-09-09	435,551	10,514	645,587	67.5%
2025-09-08	321,931	100	446,007	72.2%
2025-09-05	341,734	5,833	547,129	62.5%
2025-09-04	381,128	0	505,163	75.4%
2025-09-03	545,896	3,603	690,216	79.1%
2025-09-02	320,458	1,530	581,108	55.1%
2025-08-29	302,502	0	582,657	51.9%
2025-08-28	200,718	0	302,611	66.3%
2025-08-27	102,469	343	177,212	57.8%
2025-08-26	112,474	0	194,567	57.8%
2025-08-25	165,204	0	263,113	62.8%
2025-08-22	187,758	3,090	538,677	34.9%
2025-08-21	185,854	1,565	714,284	26.0%
2025-08-20	88,347	12	180,947	48.8%
2025-08-19	127,062	1,989	256,813	49.5%
2025-08-18	98,462	0	154,915	63.6%
2025-08-15	272,245	2,909	364,113	74.8%
2025-08-14	195,415	5,120	386,307	50.6%
2025-08-13	180,925	108	441,798	41.0%
2025-08-12	123,251	0	304,481	40.5%
2025-08-11	254,714	1,686	471,534	54.0%
2025-08-08	427,524	71	845,094	50.6%
2025-08-07	232,990	0	429,931	54.2%
2025-08-06	245,049	453	455,360	53.8%
2025-08-05	201,437	1,908	582,449	34.6%
2025-08-04	105,804	12	271,833	38.9%
2025-08-01	189,908	631	307,789	61.7%
2025-07-31	156,522	0	272,309	57.5%
2025-07-30	177,608	0	284,862	62.3%
2025-07-29	186,650	1,295	330,974	56.4%
2025-07-28	135,934	800	165,427	82.2%
2025-07-25	170,240	173	313,564	54.3%
2025-07-24	100,554	82	184,823	54.4%
2025-07-23	119,806	200	158,505	75.6%
2025-07-22	102,666	226	190,447	53.9%
2025-07-21	154,005	0	288,631	53.4%
2025-07-18	184,879	1,777	371,360	49.8%

The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.

Back to Listing

Disclaimer

All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.

Stock Name / Fund	iShares Nasdaq US Biotechnology UCITS ETF USD (Dist)
Issuer	Blackrock
ETF Ticker	BTEE(USD) LSE
ETF Ticker	BTEE.L(GBP) LSE